Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr Panitumumab PET/CT for Metastatic Lesions in Head and Neck Squamous Cell Carcinoma
NCT05747625Phase 1Recruiting
- Sponsor
- Eben Rosenthal
- Start
- May 2023
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium Zr 89 panitumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eben Rosenthal. Primary endpoints: Sensitivity of zirconium Zr 89 panitumumab at 7 years and Specificity of 89Zr-panitumumab at 7 years. Started May 2023; status: recruiting.
02
Drugs
zirconium Zr 89 panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05747625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747625.